R Maiwall1, S S Chandel1, Z Wani1, S Kumar2, S K Sarin3. 1. Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS), D1, Vasantkunj, New Delhi, 110070, India. 2. Department of Clinical Hematology, Command Hospital [Eastern Command], Kolkata, India. 3. Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS), D1, Vasantkunj, New Delhi, 110070, India. shivsarin@gmail.com.
Abstract
BACKGROUND: Systemic inflammatory response syndrome (SIRS) is associated with an increased risk of hepatic encephalopathy, renal failure, and poor outcome in patients with cirrhosis; however, there is a paucity of studies on this entity for severe alcoholic hepatitis (SAH). AIM: To evaluate SIRS at baseline as a predictor of development of acute kidney injury (AKI) and mortality in patients with SAH. METHODS: Consecutive in-patients with SAH (discriminant function ≥ 32) without AKI at baseline were followed up for the development and progression of AKI (AKIN criteria). RESULTS: Of the 365 patients (mean age 45.5 ± 9.5, 356 males), SIRS at baseline was present in 236 (64.6%). AKI developed in 122 (33.4%), of which 50 (40.9%) had progression of AKI. SIRS was associated with bacterial infections in 96 (40.6%) and in 140 (59.3%) occurred in the absence of proven infection microbiologically. The presence of SIRS predicted both AKI development (p < 0.001, OR 2.9, 95% CI 1.7-4.8) and AKI progression (p = 0.002, OR 3.27, 95% CI 1.48-7.21). Resolution of AKI also had a significant inverse association with SIRS (p = 0.001). High MELD score (p = 0.002, HR 1.1, 95% CI 1.02-1.09), in-hospital progression of AKI (p = 0.04, HR 1.54, 95% CI 1.003-2.38), and SIRS (p = 0.004, HR 1.98, 95% CI 1.25-3.1) were significant predictors of 90-day mortality (model 1), while high MELD score (p < 0.001, HR 1.1, 95% CI 1.04-1.12) and bacterial infections (p = 0.001, HR 1.8, 95% CI 1.27-2.6) were independent predictors of mortality in the second multivariate model (model 2). CONCLUSION: SIRS at admission predicts both the development of AKI and 90-day mortality in patients with SAH. This could definitely have a therapeutic and prognostic implication.
BACKGROUND: Systemic inflammatory response syndrome (SIRS) is associated with an increased risk of hepatic encephalopathy, renal failure, and poor outcome in patients with cirrhosis; however, there is a paucity of studies on this entity for severe alcoholic hepatitis (SAH). AIM: To evaluate SIRS at baseline as a predictor of development of acute kidney injury (AKI) and mortality in patients with SAH. METHODS: Consecutive in-patients with SAH (discriminant function ≥ 32) without AKI at baseline were followed up for the development and progression of AKI (AKIN criteria). RESULTS: Of the 365 patients (mean age 45.5 ± 9.5, 356 males), SIRS at baseline was present in 236 (64.6%). AKI developed in 122 (33.4%), of which 50 (40.9%) had progression of AKI. SIRS was associated with bacterial infections in 96 (40.6%) and in 140 (59.3%) occurred in the absence of proven infection microbiologically. The presence of SIRS predicted both AKI development (p < 0.001, OR 2.9, 95% CI 1.7-4.8) and AKI progression (p = 0.002, OR 3.27, 95% CI 1.48-7.21). Resolution of AKI also had a significant inverse association with SIRS (p = 0.001). High MELD score (p = 0.002, HR 1.1, 95% CI 1.02-1.09), in-hospital progression of AKI (p = 0.04, HR 1.54, 95% CI 1.003-2.38), and SIRS (p = 0.004, HR 1.98, 95% CI 1.25-3.1) were significant predictors of 90-day mortality (model 1), while high MELD score (p < 0.001, HR 1.1, 95% CI 1.04-1.12) and bacterial infections (p = 0.001, HR 1.8, 95% CI 1.27-2.6) were independent predictors of mortality in the second multivariate model (model 2). CONCLUSION: SIRS at admission predicts both the development of AKI and 90-day mortality in patients with SAH. This could definitely have a therapeutic and prognostic implication.
Entities:
Keywords:
AKI; AKI progression; SIRS; Severe alcoholic hepatitis
Authors: José Altamirano; Rosa Miquel; Aezam Katoonizadeh; Juan G Abraldes; Andrés Duarte-Rojo; Alexandre Louvet; Salvador Augustin; Rajeshwar P Mookerjee; Javier Michelena; Thomas C Smyrk; David Buob; Emmanuelle Leteurtre; Diego Rincón; Pablo Ruiz; Juan Carlos García-Pagán; Carmen Guerrero-Marquez; Patricia D Jones; A Sidney Barritt; Vicente Arroyo; Miquel Bruguera; Rafael Bañares; Pere Ginès; Juan Caballería; Tania Roskams; Frederik Nevens; Rajiv Jalan; Philippe Mathurin; Vijay H Shah; Ramón Bataller Journal: Gastroenterology Date: 2014-01-15 Impact factor: 22.682
Authors: Marlene Dominguez; Diego Rincón; Juan G Abraldes; Rosa Miquel; Jordi Colmenero; Pablo Bellot; Joan-Carles García-Pagán; Rosamelia Fernández; Montserrat Moreno; Rafael Bañares; Vicente Arroyo; Joan Caballería; Pere Ginès; Ramón Bataller Journal: Am J Gastroenterol Date: 2008-08-21 Impact factor: 10.864
Authors: Mark R Thursz; Paul Richardson; Michael Allison; Andrew Austin; Megan Bowers; Christopher P Day; Nichola Downs; Dermot Gleeson; Alastair MacGilchrist; Allister Grant; Steven Hood; Steven Masson; Anne McCune; Jane Mellor; John O'Grady; David Patch; Ian Ratcliffe; Paul Roderick; Louise Stanton; Nikhil Vergis; Mark Wright; Stephen Ryder; Ewan H Forrest Journal: N Engl J Med Date: 2015-04-23 Impact factor: 91.245
Authors: Ashwani K Singal; Sudha Kodali; Lee A Vucovich; Victor Darley-Usmar; Thomas D Schiano Journal: Alcohol Clin Exp Res Date: 2016-06-02 Impact factor: 3.455